🧠 Food for thought

Implications, context, and why it matters.

Immunai and AstraZeneca are deepening a partnership built over several years

• The agreement expands work that started in 2022, after an initial US$18 million phase focused on improving oncology trials 1.
• Immunai had raised nearly US$270 million as of September 2024, Immunai said 2.
• A 2021 funding round put the company’s valuation at about US$1 billion, giving it room for research and development work with drugmakers over several years 3.
• Immunai said 85 of its 170 employees hold PhD or MD degrees. It also said that expertise helped it secure more than 30 partnerships with Fortune 100 drug companies and leading academic institutions 2.

The agreement marks a different way AI companies work with large drugmakers

• AI biotechs are taking on a bigger role, with longer ties that place them inside research and development efforts instead of outside service work 4.
• The work now covers inflammatory bowel disease research, a group of chronic conditions that inflame the digestive tract, which extends Immunai’s platform beyond cancer programs 5.
• For Immunai, multi-year collaborations can bring repeat revenue through platform access and related services for biopharmaceutical companies and research institutions 4.
• If this approach works, other AI drug discovery firms may face pressure to prove they can deliver lasting value inside research pipelines instead of one-off projects 6.